特异性免疫治疗新进展

特异性免疫治疗(SIT)作为目前唯一可能根治变应性疾病的治疗方法,不仅可以减轻过敏症状,减少用药,还可阻止自然病程的进展,预防新变应原的产生.近年来舌下SIT因其良好的安全性、有效性和易操作性已在欧洲各国广泛开展.标准化的变应原制剂在国内外逐步应用,已取代非标准化制剂.然而无论是皮下注射还是舌下含服方法,其具体有效剂量、治疗方案、治疗疗程尚待规范统一.随着对其作用机制的不断深入研究,以及以重组变应原为主的新制剂的研发,SIT的应用范围将会进一步扩大,更好地用于变应性疾病的治疗.

New Progress of Specific Immunotherapy

Specific immunotherapy(SIT),as the only treatment which can treat the underlying cause of the allergic disease,it is not only able to reduce symptoms and needs for medication,but also prevent the progression of the allergic disease and the development of new sensitivities.During this last decade,sublingual immunotherapy has been widely used in European countries because of its excellent safety,efficacy and compliance.And the introducing of the standardized allergen products is another progress,which allow to replace the non-standardized allergen extracts.However,for both subcutaneous immunotherapy and sublingual immunotherapy,the optimal dosage,the duration and the scheme of the therapy still need to be standardized.The advances in understanding the mechanisms of SIT and the development of the new vaccine such as recombinant allergens will result in more widespread clinical use of SIT,and may allow to be better serve for the management of allergic disease.